Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026)

Invivyd's (IVVD) quarterly Liabilities and Shareholders Equity came in at $276.9 million in Q4 2025, up 113.78% YoY from $129.5 million in Q4 2024, and up 98.97% on a QoQ basis from $139.2 million in Q3 2025.

Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $276.9 million in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 113.78% year-over-year to $276.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $608.9 million (down 11.01% YoY) and the FY2025 annual result came in at $276.9 million, up 113.78% from the prior year.
  • Liabilities and Shareholders Equity climbed to $276.9 million in Q4 2025, from $139.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $686.3 million in Q3 2021 to a low of $89.1 million in Q2 2025.
  • A 5-year average of $316.7 million and a median of $276.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 428.27% — and 2025, when it plunged 51.85%.
  • Tracing IVVD's Liabilities and Shareholders Equity over 5 years: stood at $620.1 million in 2021, then sank by 38.21% to $383.2 million in 2022, then plunged by 40.19% to $229.2 million in 2023, then sank by 43.49% to $129.5 million in 2024, then soared by 113.78% to $276.9 million in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $276.9 million (Q4 2025), $139.2 million (Q3 2025), and $89.1 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Invivyd 212.23 Mn 52.15 Mn 13.01 Mn 218.88 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 218.88 Mn
Dec 31, 2025 276.88 Mn
Sep 30, 2025 139.16 Mn
Jun 30, 2025 89.14 Mn
Mar 31, 2025 103.74 Mn
Dec 31, 2024 129.52 Mn
Sep 30, 2024 161.92 Mn
Jun 30, 2024 177.35 Mn
Mar 31, 2024 215.47 Mn
Dec 31, 2023 229.18 Mn
Sep 30, 2023 274.92 Mn
Jun 30, 2023 315.41 Mn
Mar 31, 2023 350.56 Mn
Dec 31, 2022 383.17 Mn
Sep 30, 2022 424.75 Mn
Jun 30, 2022 484.61 Mn
Mar 31, 2022 556.27 Mn
Dec 31, 2021 620.09 Mn
Sep 30, 2021 686.27 Mn
Jun 30, 2021 397.99 Mn